|Bid||3,499.50 x 51000|
|Ask||3,501.50 x 53800|
|Day's range||3,470.00 - 3,503.50|
|52-week range||3,403.50 - 5,067.00|
|PE ratio (TTM)||19.85|
|Forward dividend & yield||0.26 (0.51%)|
|1y target est||N/A|
January 15, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, announced today that the European Commission (EC) has granted Marketing Authorization for ADYNOVI [Antihemophilic Factor (Recombinant), PEGylated], an extended half-life recombinant factor VIII (rFVIII) treatment, for on-demand and prophylactic use in patients 12 years and older living with hemophilia A. ADYNOVI is modified to last longer in the blood and potentially require less frequent injections than unmodified Antihemophilic Factor when used to reduce the frequency of bleeding. It is built on ADVATE® [Antihemophilic Factor (Recombinant)], a treatment used by hemophilia A patients worldwide for almost 15 years.
Shire (SHP.L) ditched its revenue target of $20 billion (14.8 billion pounds) by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance. The London-listed pharmaceutical group said total revenue would now reach $17-18 billion by 2020, dropping the goal set two years ago when it acquired haemophilia specialist Baxalta. Chief Executive Flemming Ornskov, said that revenue had tripled to $15 billion in five years and that $20 billion was a "stretch target".
Shire (Xetra: S7E.DE - news) ditched its revenue target of $20 billion by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance. The London-listed pharmaceutical group said total revenue would now reach $17-18 billion by 2020, dropping the goal set two years ago when it acquired haemophilia specialist Baxalta (Xetra: 9BX.DE - news) . Chief Executive Flemming Ornskov, said that revenue had tripled to $15 billion in five years and that $20 billion was a "stretch target".
January 8, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) ('Shire' or the 'Company'), continues to progress its strategy as the leading global biotech company focused on rare diseases. Shire expects continued revenue growth driven by a diverse portfolio of leading brands including those within its Immunology franchise, which grew 21% in the first three quarters of 2017 on a pro forma basis. In addition, Shire continues to have a promising late stage pipeline with fifteen programs currently in Phase 3. In August 2017, Shire announced that it was conducting a strategic review of its neuroscience business.
Kamada’s IV AAT Demonstrated Favorable Safety and Tolerability Profile in 10 Patients During First Six Months of Treatment, Consistent with Previously Observed Results in Other Indications Next Interim Report Expected in H2 2018 Following Completion of One Year of Treatment Top-line Results Anticipated in H2 2019
In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.
January 4, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for maribavir (SHP620), a Phase 3 investigational treatment for cytomegalovirus (CMV) infection and disease in transplant patients resistant or refractory to prior therapy. By targeting a key CMV enzyme, maribavir is thought to inhibit CMV DNA replication and encapsidation, and prevent the escape of viral capsids from the nucleids of infected cells.
Shares of Shire (SHPG) are lower on Wednesday, after the drug maker said it filed its first submission for its new plasma manufacturing facility in Georgia to the Food and Drug Administration. Cantor Fitzgerald's Louise Chen and her team write that the new facility will support Shire's immunology franchise, which has seen sales climb some 21% in 2017, easily above the 6% to 8% growth the company originally expected. SHPG guided to overall gross margins of 74.5%-76.5% in 2017 for the entire business, but did not break this out by business segments.
December 27, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, today announced that it has filed its first submission to the United States Food and Drug Administration for the company's new plasma manufacturing facility in Covington, Georgia. The first submission is for the transfer of GAMMAGARD LIQUID® [Immune Globulin Infusion (Human)] 10% Solution, a replacement therapy for primary humoral immunodeficiency (PI). The company expects to make a second submission to the FDA in 2018 for its albumin therapy, which is primarily used as plasma-volume replacement therapy in immune disorders, trauma and other critical conditions.
The U.S.-listed shares of Shire PLC fell 1.2% in premarket trade Tuesday, after the Ireland-based drug maker said a phase 2/3 trial of its treatment for Hunter syndrome in pediatric patients failed to ...
Shire Plc's investigational drug for treating pediatric patients with Hunter syndrome and cognitive impairment failed to meet the main goal of a late-stage trial. The clinical trial evaluating SHP609, ...
ZURICH, Dec (Shanghai: 600875.SS - news) 16 (Reuters) - Roche's patent dispute with London-listed Shire over the Swiss drugmaker's new haemophilia drug Hemlibra has escalated, with Shire filing a new motion in a U.S. court that Roche says aims to stop some patients from getting its medicine. Shire's motion for a preliminary injunction is part of an ongoing case in which it contends Roche infringed on a key patent to develop Hemlibra, approved in November by the U.S. Food and Drug Administration.
Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar receives approval from the European Commission.
Shares of Valeant Pharmaceuticals International (VRX) are higher Tuesday, and have easily outperformed this year, to the point that shorts may be throwing in the towel. Today, Cantor Fitzgerald's Louise Chen and her team write that the company has also seen the largest decrease in short interest in her coverage universe as of the end of November. The move comes as Valeant rose from less than $15 in mid-month to nearly $22 today.
Today, Shire (SHPG) appointed a new chief financial officer. The shares are sliding lower today after its rival Roche (RHHBY) unveiled study results that showed its Hemlibra hemophilia drug trial reduced treated bleeds in hemophilia A patients without indicators. The news is an added blow for Shire.
By Danilo Masoni and Kit Rees MILAN (Reuters) - Britain's top stock index steadied on Tuesday as Tesco (TSCO.L) rallied after it won approval for a takeover and Vodafone (VOD.L) reported strong results, ...
Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.
The pan-European STOXX 600 (.STOXX) was 0.7 percent lower at its close, with almost every sector ending in negative territory. France's EDF was the biggest faller on the day, dropping more than 10 percent after lowering its 2018 earnings and cash flow forecasts. Exane BNP Paribas affirmed its underperform rating on EDF.
France's EDF was the biggest faller on the day, dropping more than 10 percent after lowering its 2018 earnings and cash flow forecasts. This was due to lower than expected power consumption, lower availability of some of its nuclear reactors in early 2018 and a drop in capacity compensation in Britain.